Immunovant will report Q2 financial results and provide a business update on November 10, 2025, at 8:00 a.m. ET.
Quiver AI Summary
Immunovant announced it will release its financial results for the second quarter ending September 30, 2025, along with a business update on November 10, 2025, at 8:00 a.m. ET. The company invites participants to register for a conference call via a provided online link. Details for the presentation and webcast will be accessible under the "News & Events" section of its website, with an archived version available post-call. Immunovant specializes in developing therapies for autoimmune diseases, focusing on anti-FcRn technology to cater to the needs of affected individuals. Additional information about the company can be found at their website.
Potential Positives
- Immunovant is scheduled to report its financial results for the second quarter, indicating a commitment to transparency and accountability with stakeholders.
- The upcoming conference call provides an opportunity for the company to communicate its business developments and strategic initiatives to investors, potentially boosting investor confidence.
- The focus on anti-FcRn technology positions Immunovant as an innovator in the treatment of autoimmune diseases, which may enhance its reputation in the biopharmaceutical sector.
Potential Negatives
- Announcement of a financial report may indicate potential concerns about the company's financial health or performance during the quarter.
- The focus on financial results and business updates might suggest there is uncertainty or lack of significant progress in the company's strategic goals.
- The reliance on a conference call setup for discussing results could imply a need for transparency in addressing stakeholders' concerns, particularly if prior performance was lackluster.
FAQ
When will Immunovant report its financial results?
Immunovant will report its financial results for the second quarter on November 10, 2025, at 8:00 a.m. ET.
How can I access the Immunovant conference call?
To access the conference call, please register online using the provided registration link.
Where can I find presentation details for the upcoming call?
Presentation and webcast details will be available in the Investors section under “News & Events” on Immunovant's website.
What is the focus of Immunovant as a company?
Immunovant is focused on developing innovative therapies for individuals with autoimmune diseases using anti-FcRn technology.
Will there be an archived version of the conference call?
Yes, the archived webcast of the conference call will be available on Immunovant’s website after the event.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$IMVT Insider Trading Activity
$IMVT insiders have traded $IMVT stock on the open market 8 times in the past 6 months. Of those trades, 0 have been purchases and 8 have been sales.
Here’s a breakdown of recent trading of $IMVT stock by insiders over the last 6 months:
- JAY S STOUT (Chief Technology Officer) has made 0 purchases and 4 sales selling 8,429 shares for an estimated $150,889.
- MICHAEL GEFFNER (Chief Medical Officer) has made 0 purchases and 4 sales selling 7,412 shares for an estimated $133,402.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$IMVT Hedge Fund Activity
We have seen 100 institutional investors add shares of $IMVT stock to their portfolio, and 91 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- POINT72 ASSET MANAGEMENT, L.P. added 2,534,323 shares (+316.0%) to their portfolio in Q2 2025, for an estimated $40,549,168
- FMR LLC added 1,358,160 shares (+7.9%) to their portfolio in Q2 2025, for an estimated $21,730,560
- HOOD RIVER CAPITAL MANAGEMENT LLC removed 1,175,763 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $18,812,208
- VIKING GLOBAL INVESTORS LP removed 1,114,827 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $17,837,232
- MORGAN STANLEY added 999,011 shares (+76.3%) to their portfolio in Q2 2025, for an estimated $15,984,176
- T. ROWE PRICE INVESTMENT MANAGEMENT, INC. added 984,132 shares (+16.7%) to their portfolio in Q2 2025, for an estimated $15,746,112
- PRINCIPAL FINANCIAL GROUP INC removed 760,608 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $12,169,728
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$IMVT Analyst Ratings
Wall Street analysts have issued reports on $IMVT in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- JP Morgan issued a "Overweight" rating on 09/30/2025
- B of A Securities issued a "Buy" rating on 08/12/2025
To track analyst ratings and price targets for $IMVT, check out Quiver Quantitative's $IMVT forecast page.
$IMVT Price Targets
Multiple analysts have issued price targets for $IMVT recently. We have seen 5 analysts offer price targets for $IMVT in the last 6 months, with a median target of $30.0.
Here are some recent targets:
- Danielle Brill from Truist Securities set a target price of $16.0 on 10/14/2025
- Brian Cheng from JP Morgan set a target price of $33.0 on 09/30/2025
- Douglas Tsao from HC Wainwright & Co. set a target price of $35.0 on 09/04/2025
- Jason Gerberry from B of A Securities set a target price of $30.0 on 08/12/2025
- Ashwani Verma from UBS set a target price of $18.0 on 07/28/2025
Full Release
NEW YORK, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Immunovant (Nasdaq: IMVT) today announced that it will report its financial results for the second quarter ended September 30, 2025, and provide a business update at 8:00 a.m. ET on Monday, November 10, 2025.
To access the Roivant (Nasdaq: ROIV) conference call by phone, please register online using this registration link . The presentation and webcast details will also be available under “News & Events” in the Investors section of the Immunovant website at https://www.immunovant.com/investors/news-events/ir-calendar. The archived webcast will be available on Immunovant’s website after the conference call.
About Immunovant
Immunovant, Inc. is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. As a trailblazer in anti-FcRn technology, the Company is developing innovative, targeted therapies to meet the complex and variable needs of people with autoimmune diseases. For additional information on the Company, please visit
immunovant.com
.
Contacts:
Investors
Keyur Parekh
[email protected]
Media
Stephanie Lee
[email protected]
